Login to Your Account



Clinic Roundup


Tuesday, March 13, 2012
• Reviva Pharmaceuticals Inc., of San Jose, Calif., said it is enrolling patients in a Phase II study of RP503, an oral dopamine D2/serotonin 5-HT1A partial agonist and D3/D4 antagonist, in schizophrenia and schizoaffective disorder. The 228-patient study is designed to assess the drug's efficacy, safety and tolerability.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription